|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Szejniuk WM, Robles AI, McCulloch T,
Falkmer UGI and Røe OD: Epigenetic predictive biomarkers for
response or outcome to platinum-based chemotherapy in non-small
cell lung cancer, current state-of-art. Pharmacogenomics J.
19:5–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao L, Chen J, Ou B, Liu C, Zou Y and Chen
Q: GAS5 knockdown reduces the chemo-sensitivity of non-small cell
lung cancer (NSCLC) cell to cisplatin (DDP) through regulating
miR-21/PTEN axis. Biomed Pharmacother. 93:570–579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21:E9652016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song Y, Ye M, Zhou J, Wang Z and Zhu X:
Targeting E-cadherin expression with small molecules for digestive
cancer treatment. Am J Transl Res. 11:3932–3944. 2019.PubMed/NCBI
|
|
8
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De P, Carlson J, Leyland-Jones B and Dey
N: Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A
(CIP2A): An oncoprotein with many hands. Oncotarget. 5:4581–4602.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang M, Shen JF, Li P, Zhou LN, Zeng P,
Cui XX, Chen MB and Tian Y: Prognostic significance of CIP2A
expression in solid tumors: A meta-analysis. PLoS One.
13:e01996752018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Y, Gu TT and Zheng PS: CIP2A cooperates
with H-Ras to promote epithelial mesenchymal transition in
cervical-cancer progression. Cancer Lett. 356:646–655. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin YC, Chen KC, Chen CC, Cheng AL and
Chen KF: CIP2A-mediated Akt activation plays a role in
bortezomib-induced apoptosis in head and neck squamous cell
carcinoma cells. Oral Oncol. 48:585–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu HC, Chen HJ, Chang YL, Liu CY, Shiau
CW, Cheng AL and Chen KF: Inhibition of CIP2A determines
erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem
Pharmacol. 85:356–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu P, Yao J, He J, Zhao L, Wang X, Li Z
and Qian J: CIP2A down regulation enhances the sensitivity of
pancreatic cancer cells to gemcitabine. Oncotarget. 7:14831–14840.
2016.PubMed/NCBI
|
|
15
|
Zhang X, Xu B, Sun C, Wang L and Miao X:
Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: An
in vitro study. Int J Clin Exp Med. 8:16941–16947. 2015.PubMed/NCBI
|
|
16
|
Gao F, Wang X, Chen S, Xu T, Wang X, Shen
Y, Dong F, Zhong S and Shen Z: CIP2A depletion potentiates the
chemosensitivity of cisplatin by inducing increased apoptosis in
bladder cancer cells. Oncol Rep. 40:2445–2454. 2018.PubMed/NCBI
|
|
17
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2017.
View Article : Google Scholar
|
|
18
|
Ho JW, Leung YK and Chan CP: Herbal
medicine in the treatment of cancer. Curr Med Chem Anticancer
Agents. 2:209–214. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi YM, Yang L, Geng YD, Zhang C and Kong
LY: Polyphyllin I induced-apoptosis is enhanced by inhibition of
autophagy in human hepatocellular carcinoma cells. Phytomedicine.
22:1139–49. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu L, Feng J, Zheng Z, Xu H and Yu W:
Polyphyllin I inhibits the growth of ovarian cancer cells in nude
mice. Oncol Lett. 12:4969–4974. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang J, Li Y, Wang X, Hu S, Wang H, Shi
Q, Wang Y and Yang Y: Polyphyllin I suppresses human osteosarcoma
growth by inactivation of Wnt/β-catenin pathway in vitro and in
vivo. Sci Rep. 7:76052017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dong R, Guo J, Zhang Z, Zhou Y and Hua Y:
Polyphyllin I inhibits gastric cancer cell proliferation by
downregulating the expression of fibroblast activation protein
alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated
fibroblasts. Biochem Biophys Res Commun. 497:1129–1134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Q, Chen W, Xu Y, Lv X, Zhang M and
Jiang H: Polyphyllin I modulates MALAT1/STAT3 signaling to induce
apoptosis in gefitinib-resistant non-small cell lung cancer.
Toxicol Appl Pharmacol. 356:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang C, Jia X, Bao J, Chen S, Wang K,
Zhang Y, Li P, Wan JB, Su H, Wang Y, et al: Polyphyllin VII induces
apoptosis in HepG2 cells through ROS-mediated mitochondrial
dysfunction and MAPK pathways. BMC Complement Altern Med.
16:582016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Z, Liu Y, Li F, Wu J, Zhang G, Wang Y,
Lu L and Liu Z: Anti-lung cancer effects of polyphyllin vi and vii
potentially correlate with apoptosis in vitro and in vivo.
Phytother Res. 29:1568–1576. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsieh MJ, Chien SY, Lin JT, Yang SF and
Chen MK: Polyphyllin G induces apoptosis and autophagy cell death
in human oral cancer cells. Phytomedicine. 23:1545–1554. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cai X, Guo L, Pei F, Chang X and Zhang R:
Polyphyllin G exhibits antimicrobial activity and exerts anticancer
effects on human oral cancer OECM-1 cells by triggering G2/M cell
cycle arrest by inactivating cdc25C-cdc2. Arch Biochem Biophys.
644:93–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han W, Hou G and Liu L: Polyphyllin I
(PPI) increased the sensitivity of hepatocellular carcinoma HepG2
cells to chemotherapy. Int J Clin Exp Med. 8:20664–20669.
2015.PubMed/NCBI
|
|
29
|
Al Sawah E, Marchion DC, Xiong Y, Ramirez
IJ, Abbasi F, Boac BM, Bush SH, Bou Zgheib N, McClung EC,
Khulpateea BR, et al: The Chinese herb polyphyllin D sensitizes
ovarian cancer cells to cisplatin-induced growth arrest. J Cancer
Res Clin Oncol. 141:237–42. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lou W, Chen Y, Zhu KY, Deng H, Wu T and
Wang J: Polyphyllin I overcomes EMT-associated resistance to
erlotinib in lung cancer cells via IL-6/STAT3 Pathway Inhibition.
Biol Pharm Bull. 40:1306–1313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Fan L, Sun Y, Miao X, Zhang F, Meng
J, Han J, Zhang D, Zhang R, Yue Z and Mei Q: Paris saponin VII from
trillium tschonoskii reverses multidrug resistance of Adriamycin
resistant MCF-7/ADR cells via P-glycoprotein inhibition and
apoptosis augmentation. J Ethnopharmacol. 154:728–734. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Fei Z and Jiang H: Polyphyllin VII
increases sensitivity to gefitinib by modulating the elevation of
P21 in acquired gefitinib resistant non-small cell lung cancer. J
Pharmacol Sci. 134:190–196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of DDP resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu H, Li P, Li B, Sun P, Zhang J, Wang B
and Jia B: RKIP promotes Cisplatin-induced gastric cancer cell
death through NF-κB/Snail pathway. Tumour Biol. 36:1445–1153. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Y: Regulation of p53 responses by
post-translational modifications. Cell Death Differ. 10:400–403.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bode AM and Dong Z: Post-translational
modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park JH, Yang SW, Park JM, Ka SH, Kim JH,
Kong YY, Jeon YJ, Seol JH and Chung CH: Positive feedback
regulation of p53 transactivity by DNA damage-induced ISG15
modification. Nat Commun. 7:125132016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Duan C, Ji J, Zhang T, Yuan X,
Zhang Y, Ma W, Yang J, Yang L, Jiang Z, et al: Cucurbitacin B
induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1
signaling axis in human cisplatin resistant gastric cancer cells.
Oncol Rep. 38:271–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chao TT, Wang CY, Chen YL, Lai CC, Chang
FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ and Chen KF:
Afatinib induces apoptosis in NSCLC without EGFR mutation through
Elk-1-mediated suppression of CIP2A. Oncotarget. 6:2164–2179. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu P, Yao J, He J, Zhao L, Wang X, Li Z
and Qian J: CIP2A down regulation enhances the sensitivity of
pancreatic cancer cells to gemcitabine. Oncotarget. 7:14831–14840.
2016.PubMed/NCBI
|
|
41
|
Duan L and Maki CG: The IGF-1R/AKT pathway
determines cell fate in response to p53. Transl Cancer Res.
5:664–675. 2016. View Article : Google Scholar : PubMed/NCBI
|
